Gliomas are primary tumors originating from intracranial glial cells and is also one of the most common malignant intracranial tumors. The initiation and progression are often accompanied by genetic mutations， among which 40% to 60% of gliomas have epidermal growth factor receptor（ EGFR） mutations. The abnormal expression and sustained activation of EGFR promote tumor cell proliferation， migration， and survival through various downstream signaling pathways， and EGFR mutations in gliomas typically indicate poor overall survival. Therefore， EGFR targeted therapy for glioma is of great significance. A comprehensive understanding of the role and mechanisms of EGFR mutations in the initiation and progression of gliomas can help further refine potential EGFR targeted treatment strategies.